Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 194

1.

IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.

Zhang C, Moore LM, Li X, Yung WK, Zhang W.

Neuro Oncol. 2013 Sep;15(9):1114-26. doi: 10.1093/neuonc/not087. Epub 2013 Jul 21. Review.

PMID:
23877318
[PubMed - indexed for MEDLINE]
2.

Molecular pathogenesis of IDH mutations in gliomas.

Ichimura K.

Brain Tumor Pathol. 2012 Jul;29(3):131-9. doi: 10.1007/s10014-012-0090-4. Epub 2012 Mar 8. Review.

PMID:
22399191
[PubMed - indexed for MEDLINE]
3.

2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.

Jin G, Reitman ZJ, Spasojevic I, Batinic-Haberle I, Yang J, Schmidt-Kittler O, Bigner DD, Yan H.

PLoS One. 2011 Feb 4;6(2):e16812. doi: 10.1371/journal.pone.0016812.

PMID:
21326614
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Metabolism of glioma and IDH1/IDH2 mutations.

Rossetto M, Ciccarino P, Boisselier B, Labussiere M, Sanson M.

Rev Neurol (Paris). 2011 Oct;167(10):699-703. doi: 10.1016/j.neurol.2011.08.002. Epub 2011 Aug 31. Review.

PMID:
21885076
[PubMed - indexed for MEDLINE]
5.

Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?

Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ.

Lancet Oncol. 2011 Jan;12(1):83-91. doi: 10.1016/S1470-2045(10)70053-X. Epub 2010 Jul 7. Review.

PMID:
20615753
[PubMed - indexed for MEDLINE]
6.

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.

Mukasa A, Takayanagi S, Saito K, Shibahara J, Tabei Y, Furuya K, Ide T, Narita Y, Nishikawa R, Ueki K, Saito N.

Cancer Sci. 2012 Mar;103(3):587-92. doi: 10.1111/j.1349-7006.2011.02175.x. Epub 2012 Jan 13.

PMID:
22136423
[PubMed - indexed for MEDLINE]
7.

IDH1 and IDH2 mutations in gliomas.

Cohen AL, Holmen SL, Colman H.

Curr Neurol Neurosci Rep. 2013 May;13(5):345. doi: 10.1007/s11910-013-0345-4. Review.

PMID:
23532369
[PubMed - indexed for MEDLINE]
8.

[Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].

Pan Y, Qi XL, Wang LM, Dong RF, Zhang M, Zheng DF, Chang Q, Zhong YF.

Zhonghua Bing Li Xue Za Zhi. 2013 May;42(5):292-8. doi: 10.3760/cma.j.issn.0529-5807.2013.05.002. Chinese.

PMID:
24004584
[PubMed - indexed for MEDLINE]
9.

Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.

Jin G, Reitman ZJ, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA, Yang R, Lopez GY, He Y, McLendon RE, Bigner DD, Yan H.

Cancer Res. 2013 Jan 15;73(2):496-501. doi: 10.1158/0008-5472.CAN-12-2852. Epub 2012 Nov 30.

PMID:
23204232
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A.

Acta Neuropathol. 2009 Oct;118(4):469-74. doi: 10.1007/s00401-009-0561-9. Epub 2009 Jun 25.

PMID:
19554337
[PubMed - indexed for MEDLINE]
11.

IDH1 and IDH2 mutations in gliomas.

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD.

N Engl J Med. 2009 Feb 19;360(8):765-73. doi: 10.1056/NEJMoa0808710.

PMID:
19228619
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2.

Borodovsky A, Seltzer MJ, Riggins GJ.

Curr Opin Oncol. 2012 Jan;24(1):83-9. doi: 10.1097/CCO.0b013e32834d816a. Review.

PMID:
22080945
[PubMed - indexed for MEDLINE]
13.

Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.

Juratli TA, Peitzsch M, Geiger K, Schackert G, Eisenhofer G, Krex D.

Neuro Oncol. 2013 Jun;15(6):682-90. doi: 10.1093/neuonc/not006. Epub 2013 Feb 14.

PMID:
23410661
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Role of isocitrate dehydrogenase in glioma.

Alexander BM, Mehta MP.

Expert Rev Neurother. 2011 Oct;11(10):1399-409. doi: 10.1586/ern.11.134. Review.

PMID:
21955197
[PubMed - indexed for MEDLINE]
15.

IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.

Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G, Schiffer D.

J Neurooncol. 2011 Nov;105(2):345-57. doi: 10.1007/s11060-011-0596-3. Epub 2011 Jun 4.

PMID:
21643842
[PubMed - indexed for MEDLINE]
16.

Analysis of IDH1 and IDH2 mutations in Japanese glioma patients.

Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y, Suzuki H, Tominaga T.

Cancer Sci. 2009 Oct;100(10):1996-8. doi: 10.1111/j.1349-7006.2009.01270.x.

PMID:
19765000
[PubMed - indexed for MEDLINE]
17.

An in vivo patient-derived model of endogenous IDH1-mutant glioma.

Luchman HA, Stechishin OD, Dang NH, Blough MD, Chesnelong C, Kelly JJ, Nguyen SA, Chan JA, Weljie AM, Cairncross JG, Weiss S.

Neuro Oncol. 2012 Feb;14(2):184-91. doi: 10.1093/neuonc/nor207. Epub 2011 Dec 13.

PMID:
22166263
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.

Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, Lai A, Cloughesy TF, Kornblum HI, Wu H, Fantin VR, Liau LM.

J Neurooncol. 2012 Mar;107(1):197-205. doi: 10.1007/s11060-011-0737-8. Epub 2011 Oct 21.

PMID:
22015945
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients.

Zhu J, Zuo J, Xu Q, Wang X, Wang Z, Zhou D.

Med Hypotheses. 2011 Apr;76(4):602-3. doi: 10.1016/j.mehy.2011.01.011. Epub 2011 Feb 1.

PMID:
21284999
[PubMed - indexed for MEDLINE]
20.

IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients.

Metellus P, Colin C, Taieb D, Guedj E, Nanni-Metellus I, de Paula AM, Colavolpe C, Fuentes S, Dufour H, Barrie M, Chinot O, Ouafik L, Figarella-Branger D.

J Neurooncol. 2011 Dec;105(3):591-600. doi: 10.1007/s11060-011-0625-2. Epub 2011 Jun 5.

PMID:
21643985
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk